A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC
The goal of this clinical trial is to evaluate the efficacy and safety of sintilimab as adjuvant therapy in node-positive esophageal squamous cell carcinoma after radical surgery without neoadjuvant therapy. The main question it aims to answer is:

• Efficacy of sintilimab as adjuvant therapy Participants will receive sintilimab 200 mg once on day 1, every 21 days(Q3W).
Esophageal Squamous Cell Carcinoma
DRUG: sintilimab
Disease-free survival (DFS), From date of randomization until the date of first documented progression, assessed up to 36months
Overall survival (OS), From date of randomization until the date of death from any cause, assessed up to 60 months
The goal of this clinical trial is to evaluate the efficacy and safety of sintilimab as adjuvant therapy in node-positive esophageal squamous cell carcinoma after radical surgery without neoadjuvant therapy. The main question it aims to answer is:

• Efficacy of sintilimab as adjuvant therapy Participants will receive sintilimab 200 mg once on day 1, every 21 days(Q3W).